ISSN: 2167-065X

Pharmacologie clinique et biopharmaceutique

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Development and Minimizing the Carryover of A Sensitive and High Throughput LC ESI MS/MS Method for the Quantification of Rizatriptan in Human Plasma and Its Application in a Clinical Trial

Pankaj Joshi, Hanumanth Srikanth Cheruvu, Nitin Vig, Abdulla Ansari, Pankaj Singh

A simple, sensitive, and high throughput liquid chromatographic method coupled with the tandem mass spectrometry method has been developed and validated to quantify rizatriptan in human plasma using rizatriptan D 6 as an internal standard. The analyte and internal standard were extracted from plasma via solid-phase extraction and were separated on a C 18 column using methanol: 5mM ammonium acetate buffer: formic acid (80/20/0.1 v/v/v) as a mobile phase. The mass transitions m/z 270.24→201.10 and m/z 276.21→207.20 were used to measure rizatriptan and rizatriptan D 6 respectively. The proposed method validated for a linear dynamic range of 0.151-52.170 ng/mL with a correlation coefficient ≥0.999, where the regression model (1/×2) was best fitted. The carryover of the method in both aqueous and extracted blank samples after the highest concentration level (52.17 ng/mL) was less than 5% compared to the LLOQ concentration level (0.151 ng/mL). The recovery of rizatriptan at LQC, MQC, HQC levels were 79.7, 82.3, and 79.4%, respectively consistent and reproducible. The within and between batches assay precision (% CV) across the three validation batches (LLQC, LQC, MQC, and HQC) were in the range of 1.0-6.5% and 3.0-8.9% respectively. The validated method has been successfully applied to investigate a clinical pharmacokinetic study.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.